The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations

Ítems similars

• Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations
  per: Hung, Ming-Szu, et al.
  Publicat: (2018)
• Comparative Analysis of Two Methods for the Detection of EGFR Mutations in Plasma Circulating Tumor DNA from Lung Adenocarcinoma Patients
  per: Hung, Ming-Szu, et al.
  Publicat: (2019)
• Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs
  per: Lin, Jessica J., et al.
  Publicat: (2015)
• Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis
  per: Chen, Yanxin, et al.
  Publicat: (2019)
• Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma
  per: Li, Qiwen, et al.
  Publicat: (2021)